News
ENSC
2.020
-5.16%
-0.110
Weekly Report: what happened at ENSC last week (0609-0613)?
Weekly Report · 5d ago
Weekly Report: what happened at ENSC last week (0602-0606)?
Weekly Report · 06/09 10:52
Ensysce Biosciences awarded $5.3M in continued NIDA support
TipRanks · 06/04 12:20
Ensysce Biosciences Secures $5.3M In Continued NIDA Support To Advance Opioid Overdose Protection
Benzinga · 06/04 12:13
Weekly Report: what happened at ENSC last week (0526-0530)?
Weekly Report · 06/02 10:59
Weekly Report: what happened at ENSC last week (0519-0523)?
Weekly Report · 05/26 10:58
Weekly Report: what happened at ENSC last week (0512-0516)?
Weekly Report · 05/19 10:51
Ensysce Biosciences Advances in Pain Relief Innovation
TipRanks · 05/15 04:22
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $18.45 Price Valuation
Benzinga · 05/14 15:04
Ensysce Biosciences GAAP EPS of -$1.39, revenue of $1.32M
Seeking Alpha · 05/14 13:18
Ensysce Biosciences Shares Jump After Receiving Patent, Reporting 1Q Results
Dow Jones · 05/13 22:48
*Ensysce Biosciences 1Q Loss/Shr $1.39 >ENSC
Dow Jones · 05/13 21:09
Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY
Benzinga · 05/13 20:39
Ensysce Biosciences appoints Tracy Hysong as senior director, regulatory affairs
TipRanks · 05/12 13:20
Weekly Report: what happened at ENSC last week (0505-0509)?
Weekly Report · 05/12 10:51
Weekly Report: what happened at ENSC last week (0428-0502)?
Weekly Report · 05/05 10:53
Ensysce Biosciences files to sell 1.3M shares of common stock for holders
TipRanks · 05/02 20:40
Weekly Report: what happened at ENSC last week (0421-0425)?
Weekly Report · 04/28 11:00
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 04/24 17:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 04/24 12:06
More
Webull provides a variety of real-time ENSC stock news. You can receive the latest news about Ensysce Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.